Although single-agent ibrutinib has long-term efficacy and tolerability in CLL patients according to an 8-year follow-up (14), combined therapies are still needed to overcome drug resistance, further improve the efficacy of ibrutinib and reduce side effects, such as ibrutinib combined with immunochemotherapy or BCL2 inhibitor venetoclax (110, 111). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.